StocksMedium•5 November 2026•
1 min read
Cytek Biosciences Beats Q3 Estimates Despite Quarterly Loss
Key Facts
1Cytek Biosciences reported a quarterly loss of $0.05 per share, beating the Zacks Consensus Estimate of a $0.08 loss.
2The current quarter's results compare to a loss of $0.01 per share reported in the same period a year ago.
Cytek Biosciences reported a quarterly loss of $0.05 per share for the third quarter of 2026. Zacks reported that these results beat the consensus estimate, which had projected a loss of $0.08 per share. The current performance compares to a loss of $0.01 per share reported during the same period last year.
CTKB closed at $5.88 on November 4, 2026, with the stock reaching a day high of $6.09 and a low of $5.85 during the session. While the company outperformed analyst expectations for the quarter, the results reflect a widening loss relative to the prior year's third-quarter figures.